Angela Sloan

Angela Sloan

Auto-generated profile, based on publicly available information

Angela Sloan

Special Pathogens Program, National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
BWBryce Warner
Bryce Warner
LKLevi Klassen
Levi Klassen
ASAngela Sloan
Angela Sloan
YDYvon Deschambault
Yvon Deschambault
GSGeoff Soule
Geoff Soule
DSDavid Safronetz
David Safronetz
The recent emergence of the monkeypox virus (MPXV) in non-endemic countries has been designated a Public Health Emergency of International Concern by the World Health Organization. There are currently no approved treatments for MPXV infection in the United States or Canada. The antiviral drug tecovirimat (commonly called TPOXX), previously approved for smallpox treatment, is currently being deployed for treatment of MPXV infections where available based on previously accrued data. We tested the efficacy of TPOXX both in vitro and in vivo against a clade 2 Canadian 2022 isolate of MPXV isolated during the current outbreak. TPOXX prevented MPXV replication in vitro with an effective concentration in the nanomolar range. To evaluate TPOXX efficacy in vivo, we first characterized the CAST/EiJ mouse model with the same 2022 Canadian isolate. Unlike previous descriptions of this model, the Canadian isolate was not lethal in CAST/EiJ mice, although it replicated efficiently in the respiratory tract after intranasal infection. Subsequent experiments demonstrated that daily oral TPOXX treatment markedly reduced viral titers in the tissues 1 and 2 weeks after infection. Our data indicate that TPOXX is highly effective against currently circulating MPXV strains and could be an important contributor to curbing the ongoing outbreak.

6 September 2024 in Antiviral Research
Verified
Journal Article
Open access
JPJérémie Prévost
Jérémie Prévost
ASAngela Sloan
Angela Sloan
YDYvon Deschambault
Yvon Deschambault
NTNikesh Tailor
Nikesh Tailor
KTKevin Tierney
Kevin Tierney
DSDavid Safronetz
David Safronetz
While historically confined to endemic areas, Monkeypox virus (MPXV) infection has increasingly garnered international attention due to sporadic outbreaks in non-endemic countries in the last two decades and its potential for human-to-human transmission. In 2022, a multi-country outbreak of mpox disease was declared by the World Health Organization (WHO) and nearly 100,000 mpox cases have been reported since the beginning of this pandemic. The clade II variant of the virus appears to be responsible for the vast majority of these infections. While there are no antiviral drugs currently approved to treat mpox specifically, the use of tecovirimat (TPOXX®) and brincidofovir (Tembexa®) is recommended by the Centers for Disease Control and Prevention (CDC) for compassionate use in severe mpox cases, since both are FDA-approved for the treatment of the closely related smallpox disease. Given the emergence of multiple tecovirimat-resistant infections, we aimed to evaluate the treatment efficacy of brincidofovir and its active compound, cidofovir, against MPXV clade II strains. Following intranasal infection, we show that cidofovir and brincidofovir can strongly reduce the viral replication of MPXV clade IIa and IIb viruses in the respiratory tract of susceptible mice when administered systemically and orally, respectively. The high antiviral activity of both compounds against historical and currently circulating MPXV strains supports their therapeutic potential for clinical application.

13 July 2019 in Viruses
Verified
Journal Article
Open access
PDF file
BWBryce Warner
Bryce Warner
DSDerek Stein
Derek Stein
RJRohit K Jangra
Rohit K Jangra
MSMegan Slough
Megan Slough
PSPatrycja Sroga
Patrycja Sroga
DSDavid Safronetz
David Safronetz
Andes virus (ANDV) and Sin Nombre virus (SNV) are the main causative agents responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas. HCPS is a severe respiratory disease with a high fatality rate for which there are no approved therapeutics or vaccines available. Some vaccine approaches for HCPS have been tested in preclinical models, but none have been tested in infectious models in regard to their ability to protect against multiple species of HCPS-causing viruses. Here, we utilize recombinant vesicular stomatitis virus-based (VSV) vaccines for Andes virus (ANDV) and Sin Nombre virus (SNV) and assess their ability to provide cross-protection in infectious challenge models. We show that, while both rVSVΔG/ANDVGPC and rVSVΔG/SNVGPC display attenuated growth as compared to wild type VSV, each vaccine is able to induce a cross-reactive antibody response. Both vaccines protected against both homologous and heterologous challenge with ANDV and SNV and prevented HCPS in a lethal ANDV challenge model. This study provides evidence that the development of a single vaccine against HCPS-causing hantaviruses could provide protection against multiple agents.

21 February 2019 in Viruses
Verified
Journal Article
Open access
PDF file
BWBryce Warner
Bryce Warner
DSDerek Stein
Derek Stein
BGBryan D. Griffin
Bryan D. Griffin
KTKevin Tierney
Kevin Tierney
ALAnders Leung
Anders Leung
DSDavid Safronetz
David Safronetz
In North America, Sin Nombre virus (SNV) is the main cause of hantavirus cardiopulmonary syndrome (HCPS), a severe respiratory disease with a fatality rate of 35–40%. SNV is a zoonotic pathogen carried by deer mice (Peromyscus maniculatus), and few studies have been performed examining its transmission in deer mouse populations. Studying SNV and other hantaviruses can be difficult due to the need to propagate the virus in vivo for subsequent experiments. We show that when compared with standard intramuscular infection, the intraperitoneal infection of deer mice can be as effective in producing SNV stocks with a high viral RNA copy number, and this method of infection provides a more reproducible infection model. Furthermore, the age and sex of the infected deer mice have little effect on viral replication and shedding. We also describe a reliable model of direct experimental SNV transmission. We examined the transmission of SNV between deer mice and found that direct contact between deer mice is the main driver of SNV transmission rather than exposure to contaminated excreta/secreta, which is thought to be the main driver of transmission of the virus to humans. Furthermore, increases in heat shock responses or testosterone levels in SNV-infected deer mice do not increase the replication, shedding, or rate of transmission. Here, we have demonstrated a model for the transmission of SNV between deer mice, the natural rodent reservoir for the virus. The use of this model will have important implications for further examining SNV transmission and in developing strategies for the prevention of SNV infection in deer mouse populations.

30 June 2018 in Journal of Virological Methods
Verified
Journal Article
Open access
ABAlison Jane Basile
Alison Jane Basile
CGChristin Goodman
Christin Goodman
KHKalanthe Horiuchi
Kalanthe Horiuchi
ASAngela Sloan
Angela Sloan
BJBarbara W. Johnson
Barbara W. Johnson
JSJarad Schiffer
Jarad Schiffer
ZIKV IgM kits from InBios, NovaTec and Euroimmun were compared in 3 separate labs. InBios kit was most sensitive; Novatec and Euroimmun kits were most specific. Concordance across the labs was high for both the NovaTec and Euroimmun IgM + IgG kits. The NS1-based NovaTec and Euroimmun kits may be useful in confirmation of infection for a portion of patients and to reduce the number of PRNT’s required.

1 October 2017 in Antiviral Research
Verified
Journal Article
Closed access
DSDerek Stein
Derek Stein
JGJoseph Golden
Joseph Golden
BGBryan D. Griffin
Bryan D. Griffin
BWBryce Warner
Bryce Warner
CRCharlene Ranadheera
Charlene Ranadheera
DSDavid Safronetz
David Safronetz